Skip to main content
2025 IDWeek Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
Live Streamed
On Demand
On Demand
View Session Discussion + Q&A

Epi & Infection Control

Global ID

Investigative ID

Pediatric ID

Trainee
Session Type: Symposium

198 - ESPID/PIDS Joint Symposium:​ Perspectives in Pediatric Osteoarticular Infections: Bone Appetit!

Wednesday, October 22, 2025
10:30 AM - 11:45 AM US ET
Location: B206

Live Streamed On Demand
CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours
Disclosure(s):
Angela Campbell, MD, MPH, FPIDS, FIDSA: No financial relationships to disclose.
Debra Palazzi, MD, MEd: AHRQ: Grant/Research Support; AMA: Board Member, JAMA Pediatrics Associate Editor; Elsevier: writing and editing for UpToDate; Lurie Children's: Honoraria; Pediatric Infectious Disease Society (PIDS): Board Member; Pew Charitable Trust: Grant/Research Support
Adilia Warris, MD PhD: Basilea: Honoraria; Elion: Advisor/Consultant; Pfizer, Inc.: Advisor/Consultant
Allan Bybeck Nielsen, MD, PhD: No financial relationships to disclose.
Jesus Saavedra-Lozano, MD. Ph.D: Biomerieux: Satellite talk at the EBJIS Conference, October 2023 about diagnosis of BJI
Maria Carrillo-Marquez, MD, MS: Moderna ( concluded): Site PI. Phase 3 Study to Evaluate the Safety and Immunogenicity of mRNA-1273.214 Vaccine for SARS-CoV-2 Variants in 6 months <6 years; Moderna (concluded): Site PI. Phase 2 Study to Evaluate Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 Vaccine in 12 weeks to <6 months; Pfizer: Site PI. ClinicalTrials.gov identifier: NCT05639647
Romie F. Gibly, MD PhD: Coplan & Crane: Expert Testimony; Guidepoint Global: Advisor/Consultant; Lumbar Spine Research Society: Grant/Research Support; Northwestern University Clinical and Translational Sciences (NUCATS) Institute: Grant/Research Support; Orthopaedic Researcg and Education Foundation: Grant/Research Support; Pediatric Orthopaedic society of North America: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • describe available data to inform decision regarding initial vs oral IV therapy for pediatric bone and joint infections;
  • explain considerations in determining definitive antibiotic regimen and duration of therapy for pediatric bone and joint infections
  • discuss utility and outcomes using new rapid MRI technique for children with suspicion of acute hematogenous musculoskeletal infections;
  • define knowledge gaps and research needs (i.e., clinical and laboratory parameters predictive of long-term sequelae, need for surgical source control, etc.).

Presentations:

  • 10:30 AM - 10:50 AM US ET
    Initial Oral Versus IV Therapy for Bone and Joint Infections (Europe)

    Speaker: Allan Bybeck Nielsen, MD, PhD (he/him/his) – Copenhagen University Hospital, Hvidovre

  • 10:50 AM - 11:10 AM US ET
    Determining Definitive Antibiotic Regimen and Duration of Therapy (U.S.)

    Speaker: Maria Carrillo-Marquez, MD, MS – University of Tennessee Health Science Center College of Medicine

  • 11:10 AM - 11:30 AM US ET
    Rapid MRI Protocol for Pediatric Musculoskeletal Infections (U.S.)

    Speaker: Romie F. Gibly, MD PhD – Orthopaedic Surgery, Northwestern University Feinberg School of Medicine, Ann & Robert H Lurie Children's Hospital of Chicago

  • 11:30 AM - 11:45 AM US ET
    Defining the Research Needs in Pediatric Osteoarticular Infections (Europe)

    Speaker: Jesus Saavedra-Lozano, MD. Ph.D – Complutense University of Madrid and Department of Pediatrics, Infectious Disease Unit, Gregorio